Idorsia announced results from the phase 3 MODIFY trial which evaluated lucerastat as monotherapy for the treatment of adult patients with Fabry disease. The trial…
AbbVie announced positive top-line results from the two Phase 3 studies conducted under the moniker SELECT-AXIS 2. SELECT-AXIS 2 was conducted as a master study protocol with two standalone studies with…
Retrotope reported data from its Phase 2/3 clinical trial of RT001 in patients with infantile neuroaxonal dystrophy (INAD) and its concurrent natural history study of disease…
Xenon Pharmaceuticals reported positive topline results from the Phase 2b X-TOLE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive…
Janssen presented results from the phase 2b CYPRESS trial as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2. Results showed the RSV vaccine to be highly effective…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
